akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Company profile
Ticker
AKTX
Exchange
Website
CEO
Gur Roshwalb
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
SEC CIK
Corporate docs
Subsidiaries
Celsus Therapeutics Inc. • Morria Biopharma Ltd. • Volution Immuno Pharmaceuticals SA • Akari Malta Limited ...
AKTX stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Apr 24
8-K
Akari Therapeutics Reports Full-Year
1 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
425
Business combination disclosure
11 Mar 24
8-K
Entry into a Material Definitive Agreement
11 Mar 24
425
Business combination disclosure
5 Mar 24
425
Business combination disclosure
5 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
D
$2.00 mm in equity / securities to be acquired, sold $2.00 mm, 2 investors
9 Jan 24
8-K
Akari Therapeutics Announces Existing Investors Support the Company
2 Jan 24
Latest ownership filings
SC 13D/A
RPC Pharma Ltd
4 Jan 24
3
Rachelle Suzanne Jacques
2 Jan 24
3
WENDY F DICICCO
2 Jan 24
3
Samir Rashmikant Patel
2 Jan 24
3
Mohamed Wa'el Ahmed Hashad
2 Jan 24
3
Raymond Prudo-Chlebosz
2 Jan 24
3
Michael Grissinger
2 Jan 24
3
DONALD A WILLIAMS
2 Jan 24
SC 13D/A
RPC Pharma Ltd
20 Oct 23
SC 13D/A
RPC Pharma Ltd
14 Apr 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 12 |
Increased positions | 0 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.17 bn |
Total shares | 801.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
RPC Pharma | 800.77 mm | $145.50 mm |
Sabby Management | 178.09 k | $703.46 mm |
Omnia Family Wealth | 59.12 k | $233.51 mm |
NEA Management | 22.61 k | $89.30 mm |
Truvestments Capital | 50.00 | $198.00 k |
Cornerstone Planning | 5.00 | $20.00 k |
Proequities | 0.00 | $0.00 |
Press releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
18 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
15 Mar 24
Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm
15 Mar 24
INVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK
9 Mar 24
Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm
8 Mar 24